Skip to: [Content] [Navigation]

For additional information contact:
Rich Dewit, MEDRAD Computed Tomography Business Unit
412-767-2400 ext. 3569
rdewit@medrad.com

Dan Dieter, MEDRAD Marketing Services
724-940-6949
ddieter@medrad.com

FOR IMMEDIATE RELEASE

MEDRAD® XDSTM Extravasation Detector Wins Medical Design Excellence Award

Stellant® CT Injection System Technology Detects Extravasations during CT Contrast Injections

WARRENDALE, Pa., May 22, 2008 — MEDRAD, INC., announced today that its XDS™ Extravasation Detector has received a 2008 Medical Design Excellence Award® (MDEA). The XDS employs a technology that aids in the detection of leaking intravenous contrast media from the injection site into surrounding tissue during computed tomography (CT) diagnostic studies.

“This prestigious award recognizes our XDS Extravasation Detector technology, the investment of many resources for research and development, and the inherent risk of developing medical devices; the MDEA validates that the investment and risk were worth it,” said Cliff Kress, senior vice president, MEDRAD CT Business Unit. “We are proud that we have succeeded in developing an extravasation technology that continues MEDRAD’s long-standing commitment to patient safety.”    

The MDEA competition, presented by Canon Communications LLC and sponsored by Medical Device & Diagnostic Industry Magazine, recognizes medical product excellence in design and engineering features, innovative use of materials, user-related functions that improve healthcare delivery, features that benefit patients, and the ability of the development team to overcome challenges. An impartial, multi-disciplinary panel of jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics reviewed the entries and selected the winners.

MEDRAD and development partner, Battelle Medical Device Solutions, will accept the award at a ceremony June 4 at the Medical Design & Manufacturing (MD&M) East 2008 Conference and Exposition in New York City.

More information on the XDS Extravasation Detector is available on the MEDRAD Web site at www.medrad.com/products/ct/xds-extravasation-detector.html.

MEDRAD INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services.  Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

###

back to top